Abbott, Merck, Pfizer raising the bar

Share this article:
Abbott Labs stands out as a leader in marketing research, according to a panel discussion at CBI’s 2nd Annual Pharmaceutical Market Research Summit in Philadelphia at the end of April.

“Their business analysts are very personable and you end up with a tight delivery,” said Peter Simpson, president, Segmedica.

 “They are great at integrating information into what they do daily,” added John Tapper, chief strategy officer, Ziment.

Merck was among the large companies given the thumbs-up by the panel. “Merck is a great example of a company getting, and implementing, strategies in the entire space,” said Meredith Abreu, VP at Manhattan Research. “They are very good at getting information out there.”

Pfizer also drew praise. “The brands act like smaller companies,” said Simpson, “so when you go in you are reporting it your way.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.